Altemia™ Receives Orphan Drug Designation from the European Medicines Agency for the Treatment of Pediatric Patients with Sickle Cell Disease (SCD)

The European Commission has granted Orphan Designation in the European Union (EU) to Altemia, the Company’s novel oral formulation being developed for the treatment of SCD in pediatric patients.

read more…

Micelle Bio Pharmaceutical to Present New Research on Altemia™ to Treat Sickle Cell Disease at the ASPHO Conference

Micelle BioPharma Inc. will present new research data from the Phase 2 study (SCOT trial) on SC411 (Altemia) at the 2018 American Society Pediatric Hematology and Oncology (ASPHO) meeting, being held in Pittsburgh, PA , May 2-5, 2018.

read more…

Altemia™ Achieves Successful Clinical Results in Pediatric Patients with Sickle Cell Disease (SCD)

  • Statistically significant results confirm the mechanism of action of Altemia for the treatment of SCD
  • Primary and secondary endpoints were met
  • A clinically meaningful reduction of vaso-occlusive crises (VOCs) was observed in the top line results

read more…


The Centers for Disease Control and Prevention estimates that SCD affects 1 out of every 365 black or African-American babies, and 1 out of every 16,300 Hispanic-American babies.

Working with Congress to improve understanding and work for affordable solutions.

Symptoms of sickle cell disease usually begin in early childhood. Symptoms vary in intensity from person to person, a result of a complex interplay of genetics, cellular and environmental factors. Beginning in childhood, patients with sickle cell disease suffer recurrent crises of severe pain. These crises are unpredictable and are caused by blocked blood flow to organs and extremities.